Alvez Fernando Lopez, de Souza Anita Avila, de Mello Julia Eisenhardt, Pedra Nathalia Stark, Goularte Kelen Cristiane Machado, Assmann Charles Elias, Schirmann Adriel Antônio, Mostardeiro Vitor Bastianello, Gutierres Jessié Martins, da Cruz Fernandes Marilda, Chitolina Schetinger Maria Rosa, Stefanello Francieli Moro, Tavares Rejane Giacomelli, de Aguiar Mayara Sandrielly Soares, Spanevello Roselia Maria
Graduate Program in Biochemistry and Bioprospecting - Laboratory of Neurochemistry, Inflammation, and Cancer, Center for Chemical, Pharmaceutical, and Food Sciences, Federal University of Pelotas, Campus Universitário S/N, Capão do Leão, RS, Brazil.
Graduate Program in Biochemistry and Bioprospecting - Laboratory of Neurochemistry, Inflammation, and Cancer, Center for Chemical, Pharmaceutical, and Food Sciences, Federal University of Pelotas, Campus Universitário S/N, Capão do Leão, RS, Brazil.
Eur J Pharmacol. 2025 Sep 15;1003:177987. doi: 10.1016/j.ejphar.2025.177987. Epub 2025 Jul 22.
Neuroinflammation is a defense mechanism of the central nervous system triggered by tissue injury and involves astrocytes and microglia. Upon activation, both release cytokines and reactive species, contributing to the inflammatory response. The cholinergic system, known for its role in neurotransmission, also plays an anti-inflammatory role, mediated by acetylcholine (ACh). In this context, compounds capable of modulating neuroinflammation are vital for developing therapeutic strategies to mitigate neurodegenerative diseases and promote brain health. Thiazolidinones have emerged as promising candidates, owing to their antioxidant, anti-inflammatory, and anticholinesterase properties. The aim of this study was to evaluate the effects of 2-(4-(methylthio)phenyl)-3-(3-(piperidin-1-yl)propyl)thiazolidin-4-one (DS12) on lipopolysaccharide (LPS)-induced neuroinflammation in mice. Adult male Swiss mice were divided into groups: I) Control, II) LPS (250 μg/kg), III) LPS (250 μg/kg) plus DS12 (5 mg/kg), and IV) LPS (250 μg/kg) plus DS12 (10 mg/kg). Mice received LPS and DS12 for seven consecutive days. Food consumption, body weight, locomotion, memory, cholinergic function, oxidative stress parameters, glial reactivity, and cytokine levels were assessed. LPS reduced food intake and weight gain, memory deficits, and increased oxidative damage in the cerebral cortex, striatum, and hippocampus. Additionally, LPS increased acetylcholinesterase activity and M1mACh receptor expression, as well as markers of glial reactivity and cytokine levels in the hippocampus. Treatment with DS12 effectively mitigated these alterations induced by LPS. In conclusion, DS12 shows potential in protecting against neuroinflammation, supporting its use as a promising candidate for therapeutic strategies targeting neurodegenerative diseases.
神经炎症是由组织损伤触发的中枢神经系统防御机制,涉及星形胶质细胞和小胶质细胞。激活后,二者都会释放细胞因子和活性物质,促进炎症反应。以其在神经传递中的作用而闻名的胆碱能系统,也通过乙酰胆碱(ACh)发挥抗炎作用。在此背景下,能够调节神经炎症的化合物对于制定减轻神经退行性疾病和促进大脑健康的治疗策略至关重要。噻唑烷二酮因其抗氧化、抗炎和抗胆碱酯酶特性,已成为有前景的候选药物。本研究的目的是评估2-(4-(甲硫基)phenyl)-3-(3-(哌啶-1-基)propyl)噻唑烷-4-酮(DS12)对脂多糖(LPS)诱导的小鼠神经炎症的影响。成年雄性瑞士小鼠分为几组:I)对照组,II)LPS(250μg/kg)组,III)LPS(250μg/kg)加DS12(5mg/kg)组,和IV)LPS(250μg/kg)加DS12(10mg/kg)组。小鼠连续七天接受LPS和DS12。评估食物消耗、体重、运动、记忆、胆碱能功能、氧化应激参数、胶质细胞反应性和细胞因子水平。LPS减少了食物摄入量和体重增加,导致记忆缺陷,并增加了大脑皮层、纹状体和海马体中的氧化损伤。此外,LPS增加了乙酰胆碱酯酶活性和M1mACh受体表达,以及海马体中胶质细胞反应性和细胞因子水平的标志物。DS12治疗有效减轻了LPS诱导的这些改变。总之,DS12在预防神经炎症方面显示出潜力,支持其作为针对神经退行性疾病治疗策略的有前景候选药物。